

2021 Korean Association for Lung Cancer International Conference _ Oral Presentation Schedule

No	Time	Subject	Presenting Author	
Presentation Date & Time: November 25, 2021 / 10:10-11:25				
O1-1	10:10-10:19	Development of Detection and Virtual Biopsy Model for Early-Lung Adenocarcinoma Using Diagnostic Chest Based on Machine Learning Algorithm	Juyoung Lee	Yonsei University
O1-2	10:19-10:28	Exosomal miR-1260b Derived from Non-Small Cell Lung Cancer Promotes Tumor Metastasis through the Inhibition of HIPK2	Dong Ha Kim	University of Ulsan
O1-3	10:28-10:37	Clinical Usefulness of Serum KL-6 Test for Predicting Occurrence and Assessing Severity of Treatment-Related Interstitial Lung Disease in Lung Cancer: A Single Center Cohort Study	Hwa-Kyung Park	Chonnam National University
O1-4	10:37-10:46	The Effects of Statin Use on Lung Cancer Development in Patients with Idiopathic Pulmonary Fibrosis Using Clinical Data Warehouse	Hye Seon Kang	The Catholic University of Korea
O1-5	10:46-10:55	Contribution of p53 in Sensitivity to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer	Kyungtaek Im	University of Ulsan
O1-6	10:55-11:04	Spatial Cell Types Mapping from H&E-Stained Tumor Tissue Images via Deep Learning Trained by Spatial Transcriptomic Data of Lung Adenocarcinoma	Kwon Joong Na	Seoul National University
O1-7	11:04-11:13	Effectiveness of Cloud-Based Quality Control System Using Computer Program in a Korean National Lung Cancer Screening Program	Ji-Youn Song	National Cancer Center
O1-8	11:13-11:22	Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Patients with Treatment-Naïve Stage IV Non-Small Cell Lung Cancer	Bo-Guen Kim	Sungkyunkwan University
Presentation Date & Time: November 26, 2021 / 10:10-11:25				
O2-1	10:10-10:19	A Prospective Phase 2 Study of Rapid Detection and EGFR-TKI Initiation by EV-Based BALF Liquid Biopsy in Advanced NSCLC Patients	In Ae Kim	Konkuk University
O2-2	10:19-10:28	Overall Survival with Afatinib as First-Line Therapy for Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in KATRD EGFR Cohort	Sung Yong Lee	Korea University
O2-3	10:28-10:37	Efficacy and Safety of Lazertinib 240 mg in Patients with EGFR T790M Mutant NSCLC: Data from a Phase I/II Study	Byoung Chul Cho	Yonsei University
O2-4	10:37-10:46	Sequential Afatinib and Osimertinib in Asians with EGFR Mutation-Positive NSCLC and T790M-Mediated Acquired Resistance: Combined Analysis of Two Non-Interventional Studies	Hyun Ae Jung	Sungkyunkwan University
O2-5	10:46-10:55	High Tumor Mutation Burden Predicts Unfavorable Clinical Outcomes in EGFR-Mutated Lung Adenocarcinoma Treated with Targeted Therapy	Seung Hyeun Lee	Kyung Hee University
O2-6	10:55-11:04	Combination Osimertinib Plus Selpercatinib for EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET Fusions	Ari Jeon	Eli Lilly and Company
O2-7	11:04-11:13	Effect of N-acetylcysteine on Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients	Jun Hyeok Lim	Inha University
O2-8	11:13-11:22	Efficacy and Safety of Selpercatinib (LOXO-292) in East-Asian Patients with RET Fusion-Positive NSCLC	Se Hoon Lee	Sungkyunkwan University
Presentation Date & Time: November 26, 2021 / 13:00-14:40				
O3-1	13:00-13:09	Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated with Neoadjuvant CCRT Followed by Surgery	Sehhoon Park	Sungkyunkwan University
O3-2	13:09-13:18	Vision Artificial Intelligence Factor in Image Registration for Lung Stereotactic Body Radiotherapy	Kaile Li	Varian Medical System
O3-3	13:18-13:27	Phase 1 Trial Evaluating Safety of the Macrophage Target Sentinel Lymph Node Tracer (99mTc-MSA) Combined with Indocyanine Green for Intraoperative Sentinel Lymph Nodes Detection in Lung Cancer Surgery	Jun Hee Lee	Korea University
O3-4	13:27-13:36	Treatment Outcomes of Re-Irradiation Using Stereotactic Ablative Radiotherapy to Lung: A Propensity Score Matching Analysis	Tae Hoon Lee	Seoul National University
O3-5	13:36-13:45	Consolidative High-Dose Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer in Korea	Juwhan Choi	Korea University
O3-6	13:45-13:54	A Propensity-Matched Real-world Data Analysis of Durvalumab after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer	Cheol-Kyu Park	Chonnam National University
O3-7	13:54-14:03	Low-Level Expression of Necroptosis Factors Indicates a Poor Prognosis of the Squamous Cell Carcinoma Subtype of Non-Small-Cell Lung Cancer	Jun Hyeok Lim	Inha University
O3-8	14:03-14:12	Prognostic Significance of Extracapsular Extension in Patients with Pathologic N1 Non-Small Cell Lung Cancer Undergoing Complete Resection	Jae Kwang Yun	University of Ulsan
O3-9	14:12-14:21	Optimization of Indocyanine Green for Intraoperative Fluorescence Image-guided Thoracoscopic Resection of Lung Cancer	Yu Hua Quan	Korea University
O3-10	14:21-14:30	Radiotherapy for Resected Non-Small Cell Lung Cancer in Elderly Patients	Yoon Young Jo	University of Ulsan
O3-11	14:30-14:39	Is Moderate-Intensity Stereotactic Body Radiation Therapy Feasible for Ultra-Central Lung Cancer?: Updated Results	Chai Hong Rim	Korea University